AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for children aged six and older living with moderate-to-severe plaque...
GSK plc and Spero Therapeutics announced that the US Food and Drug Administration (FDA) has approved Utebzi(tebipenem pivoxil). It is indicated for adult patients with complicated urinary tract...